BioSpace News Archive

ESSA Pharma Inc. today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform.

RapidA will showcase its clinical expertise and industry-leading innovation at the American Heart Association’s International Stroke Conference (ISC) in Phoenix, AZ, February 7-9.

Evaxion Biotech A/S today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares.

bioAffinity Technologies today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company’s Medical and Scientific Advisory Board.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic’s C1 filamentous fungal based microbial protein production platform.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+.

Simulations Plus, Inc. today announced that it will participate in two healthcare conferences in February.

ValGenesis Inc. and Amaris Consulting, have partnered to introduce the ValGenesis product suite alongside Amaris Consulting’s immense expertise across the life sciences sector in the European Union (EU) and Latin America (LATAM).

BioMarin Pharmaceutical Inc. today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.